Last reviewed · How we verify
Clopidogrel and Esomeprazole
At a glance
| Generic name | Clopidogrel and Esomeprazole |
|---|---|
| Also known as | Plavix, Nexium |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects (PHASE1)
- The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers
- A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program (NA)
- Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants (PHASE1)
- YouScript IMPACT Registry
- Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer (PHASE2)
- Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects (PHASE4)
- A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel and Esomeprazole CI brief — competitive landscape report
- Clopidogrel and Esomeprazole updates RSS · CI watch RSS
- Takeda portfolio CI